Metrics as of 10/16/2026, 08:34 AM (Berlin time), refresh in progress.
Palisade Bio Stock
Palisade Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- J. D. Finley
- Employees
- 14
- Market cap
- $246 M
- IPO
- 30/03/2007
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat…
Palisade Bio stock: price history
1D
+4.1%
1W
+6.2%
1M
-23.8%
6M
-33.9%
YTD
-34.5%
1Y
-11.0%
2Y
-56.6%
5Y
-99.9%
10Y
-100.0%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~58% stronger price swings than usual
Ask the agents about Palisade Bio
Analyst assessment of Palisade Bio
PRICE TARGET LOW
US$2.00
CONSENSUS
US$4.50
MEDIAN
US$4.50
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 13/10/2026
Palisade Bio stock metrics
P/E
-2.9
P/B
2.67
EV/EBITDA
-4.31
RETURN ON EQUITY
-8.7%
NET MARGIN
-2,114.8%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.2%
FLOAT SHARES
160,722,127
AVG. DAILY VOLUME (30D)
3,314,838
Insider transactions (SEC)
Finley John David
Finley John David
Jones Mitchell Lawrence
Jones Mitchell Lawrence
Williams Donald Allen
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Palisade Bio stock
What does Palisade Bio do?
Palisade Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is J. D. Finley, the company employs around 14 people.
The IPO was on 30/03/2007; the stock trades on NASDAQ under the ticker PALI.
What do analysts say about Palisade Bio stock?
4 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$4.50, ranging from US$2.00 to US$7.00, with a median of US$4.50.
This is an external assessment, not a statement by Market Jury.
When does Palisade Bio report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 58% stronger than usual.
Does Palisade Bio pay a dividend?
No, Palisade Bio currently does not pay a dividend.
Which stocks are comparable to Palisade Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Palisade Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Palisade Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.